Trial intelligence / Profile preview

PF-08634404 plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated metastatic colorectal cancer

2025-523521-18-00Phase 3Authorised

Sponsor: Pfizer
Start: Jun 2026
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Countries: 20

Overview

Phase 3, randomised, double-blind trial of PF-08634404 in metastatic colorectal adenocarcinoma (mCRC) and colorectal adenocarcinoma (2 arms), sponsored by Pfizer. Primary endpoints: Progression-free survival by blinded independent central review and Overall survival. Planned start Jun 2026; status: authorised.

Drugs

PF-08634404

Conditions

metastatic colorectal adenocarcinoma (mCRC)colorectal adenocarcinoma

Beyond the preview

Go deeper on 2025-523521-18-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-523521-18-00.